SOURCE: CryoPort Systems, Inc.

CryoPort Systems, Inc.

January 14, 2010 17:05 ET

CryoPort Announces Agreement With FedEx Express for the CryoPort Express® Shipping Solution

LAKE FOREST, CA--(Marketwire - January 14, 2010) - CryoPort, Inc. (OTCBB: CYRX) today announced that the company has signed an agreement for FedEx Express to be the first global carrier to have available the innovative CryoPort Express® Shipping solution for customers.

Larry Stambaugh, CEO of CryoPort, stated, "I'm extremely pleased to have solidified this agreement with one of the largest global carriers and a Fortune 100 company. We have worked extremely hard at putting together the right product that FedEx customers have an option for improved sample integrity to ship high value biologics, clinical samples and other materials requiring a frozen solution. The FedEx global network when combined with the breakthrough innovation of the validated CryoPort Express® shipper offers an improved frozen shipping solution for the life science industry."

Unlike dry ice shipping that often requires re-icing during transit, the CryoPort Express® Shipper maintains frozen temperatures below -150C for 10+ days. This technology revolutionizes the frozen shipping model that today requires dry ice, shipping boxes, arranging for the transportation and packing of the boxes with dry ice and the samples. In addition, by eliminating dry ice from the equation, the CryoPort Express® Shipper eliminates the hazardous, costly and restrictive nature of shipping dry ice on aircraft. It also eliminates the need for re-icing operations and the purchase, storage and disposal of non-environmentally friendly materials like Styrofoam boxes and inserts.

About CryoPort, Inc.

CryoPort ( has developed a leading edge, proprietary, technology driven packaging and transport and packaging system focused on providing a solution for the frozen shipping market in the growing global life science industry. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex logistical environment.


This press release contains forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information

  • Contact:
    Stuart Fine
    Carpe DM, Inc.